Earnings Call Insights: Roche Holding AG (OTCQX ... year," with overall group sales growing 7%, driven by 9% growth in the ...

Roche first-quarter ... Analysts had estimated sales at CHF14.35 billion, according to a Visible Alpha compiled consensus. Sales in the pharmaceutical and diagnostics divisions both fell 6% ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

“Our discovery philosophy is very patient-centric and Roche’s strength to integrate pharma and diagnostics is unique in the industry.” ...

Roche has announced a new 'open innovation' research alliance in nanotechnology to develop new diagnostic tools. The Swiss company is to work with BioMed X, a new open innovation lab in Heidelberg ...

Roche also announced the initiation of a Phase ... with a Phase III trontinemab programme and continue to expand our diagnostic solutions,” said Levi Garraway, M.D., Ph.D., Roche’s Chief ...

New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa BrainshuttleTM AD study Data on the Elecsys® pTau181 plasma test demonstrate ...